Analyst Ratings for CytomX Therapeutics (CTMX) [Neutrals]
CTMX Rating Summary
CTMX Price Target Summary
- Highest: $3.25 (BMO Capital)
- Lowest: $2.50 (Jefferies)
- Average: $2.92
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$2.92 (+82.3%)
* Over Last 12-Mos
Rating Score: 4.1 / 10 Percentile Rank: 41%
Rating Score: 4.1 / 10 Percentile Rank: 41%
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
4/22/2024 | JPMorgan | Anupam Rama | Upgrade | Neutral (Underweight) |
N/A (N/A) |
1.73 (1.60) |
-7.51% | Details |
11/14/2022 | BMO Capital » Updated 3/12/2024 |
Etzer Darout | Downgrade | Market Perform (Outperform) |
3.25 (3.30) |
1.29 (1.60) |
24.03% | Details |